Research And Development

Shaping the future of noninvasive diagnostics with artificial intelligence.

Strong Scientific Expertise

Widely used, researched and validated patented test

0
Studies published
By
0
Authors
In
0
Journals

Evaluating serum biomarkers LiverFast surrogates of liver fibrosis and steatosis could identify risks in a clinical population experiencing sars-cov2 infection (COVID).

Lead Author

Dr. Maryna Raskin

Study Population

Miscellaneous n=10,623
LIVERFASt™ & LIVERFASt Select

Conclusion

LIVERFASt™ Steatosis and Fibrosis scores are NITs that could be used to screen populations at risk of MetS and liver disease to identify those at risk of COVID-19.

Location

Health Catalyst US

Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis.

Lead Author

Dr. Brian Cohn

Study Population

IT simulations
10,000 replicates per biomarker

Conclusion

Noise injection allows for nuanced tailoring & interpretation of results inferred by an AIA. We equip clinicians with an interactive tool to contextualize therapeutic expectations & aid in patient education towards adherence endpoints. In effect, providing a new, nuanced view of how AIA assess LD.

Location

Fibronostics US

Machine learning technology for evaluation of liver fibrosis, inflammation activity and steatosis (LiverFast™).

Lead Author

Abhishek Aravind

Study Population

NAFL to advanced NASH n=2862
LIVERFASt™

Conclusion

The modified SAF scoring system generated by LIVERFASt™ provided a simple & convenient diagnosis of NAFLD & NASH, and staging of the three liver lesions as shown in a cohort of SEA.

Location

Fibronostics Singapore

Predictive value of non-invasive methods liverfast, acoustic radiation force impulse (ARFI), fib-4 & apri to identify the natural phases of chb infection from nuh chb study cohort of singapore.

Lead Author

Prof. Lim Seng Gee

Study Population

CHB n=724, LIVERFASt™

Conclusion

LF-Fibrosis & LF-Activity are reliable tools for screening HBV infected patients & for detecting phase-related liver disease, with better NPV than APRI or FIB-4. Management of HBV pts could be improved by LF tests.

Location

National University Health System (NUHS) Singapore